{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:52:08Z","timestamp":1794621128961,"version":"4.9.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12325-025-03124-8","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:44:25Z","timestamp":1739976265000},"page":"1800-1810","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase\u00a03 Trials"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct02395133","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-7786","authenticated-orcid":false,"given":"Sonja","family":"St\u00e4nder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-1822","authenticated-orcid":false,"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0853-0252","authenticated-orcid":false,"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8100-7161","authenticated-orcid":false,"given":"Brian S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0773-0554","authenticated-orcid":false,"given":"Kenji","family":"Kabashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-550X","authenticated-orcid":false,"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-9976","authenticated-orcid":false,"given":"Martin","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8347-7426","authenticated-orcid":false,"given":"Mike","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"3124_CR1","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s13555-023-00920-4","volume":"13","author":"SM Ferrucci","year":"2023","unstructured":"Ferrucci SM, Tavecchio S, Marzano AV, Buffon S. Emerging systemic treatments for atopic dermatitis. Dermatol Ther (Heidelb). 2023;13:1071\u201381. https:\/\/doi.org\/10.1007\/s13555-023-00920-4.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"3124_CR2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396:345\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)31286-1.","journal-title":"Lancet"},{"key":"3124_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00408-023-00603-z","volume":"201","author":"AH Khan","year":"2023","unstructured":"Khan AH, Gouia I, Kamat S, Johnson R, Small M, Siddall J. Prevalence and severity distribution of type\u00a02 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis. Lung. 2023;201:57\u201363. https:\/\/doi.org\/10.1007\/s00408-023-00603-z.","journal-title":"Lung"},{"key":"3124_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2022.100131","volume":"2","author":"LA Beck","year":"2022","unstructured":"Beck LA, Cork MJ, Amagai M, et al. Type\u00a02 inflammation contributes to skin barrier dysfunction in atopic dermatitis. JID Innov. 2022;2:100131. https:\/\/doi.org\/10.1016\/j.xjidi.2022.100131.","journal-title":"JID Innov"},{"key":"3124_CR5","doi-asserted-by":"publisher","first-page":"adv00402","DOI":"10.2340\/00015555-3751","volume":"101","author":"M de Bruin-Weller","year":"2021","unstructured":"de Bruin-Weller M, Biedermann T, Bissonnette R, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101:adv00402. https:\/\/doi.org\/10.2340\/00015555-3751.","journal-title":"Acta Derm Venereol"},{"key":"3124_CR6","doi-asserted-by":"publisher","first-page":"adv5382","DOI":"10.2340\/actadv.v103.5382","volume":"103","author":"M de Bruin-Weller","year":"2023","unstructured":"de Bruin-Weller M, Deleuran M, Biedermann T, et al. The treat-to-target project in atopic dermatitis: one year on. Acta Derm Venereol. 2023;103:adv5382. https:\/\/doi.org\/10.2340\/actadv.v103.5382.","journal-title":"Acta Derm Venereol"},{"key":"3124_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40257-023-00827-y","volume":"25","author":"C Vestergaard","year":"2024","unstructured":"Vestergaard C, Skovsgaard C, Johansen C, Deleuran M, Thyssen JP. Treat-to-target in atopic dermatitis. Am J Clin Dermatol. 2024;25:91\u20138. https:\/\/doi.org\/10.1007\/s40257-023-00827-y.","journal-title":"Am J Clin Dermatol"},{"key":"3124_CR8","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","volume":"384","author":"S St\u00e4nder","year":"2021","unstructured":"St\u00e4nder S. Atopic dermatitis. N Engl J Med. 2021;384:1136\u201343. https:\/\/doi.org\/10.1056\/NEJMra2023911.","journal-title":"N Engl J Med"},{"key":"3124_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/03007995.2019.1699516","volume":"36","author":"DM Pariser","year":"2020","unstructured":"Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis\u00a0Control Tool (ADCT). Curr Med Res Opin. 2020;36:367\u201376. https:\/\/doi.org\/10.1080\/03007995.2019.1699516.","journal-title":"Curr Med Res Opin"},{"key":"3124_CR10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121:340\u20137. https:\/\/doi.org\/10.1016\/j.anai.2018.07.006.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3124_CR11","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase\u00a03 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1610020.","journal-title":"N Engl J Med"},{"key":"3124_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.644760","volume":"8","author":"FJ Legat","year":"2021","unstructured":"Legat FJ. Itch in atopic dermatitis \u2013 what is new? Front Med (Lausanne). 2021;8:644760. https:\/\/doi.org\/10.3389\/fmed.2021.644760.","journal-title":"Front Med (Lausanne)"},{"key":"3124_CR13","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jaad.2023.01.053","volume":"89","author":"J Yeung","year":"2023","unstructured":"Yeung J, Gooderham MJ, Hong HC, et al. Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: a Canadian perspective. J Am Acad Dermatol. 2023;89:372\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2023.01.053.","journal-title":"J Am Acad Dermatol"},{"key":"3124_CR14","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase\u00a03 trial. Lancet. 2017;389:2287\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1.","journal-title":"Lancet"},{"key":"3124_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","volume":"74","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase\u00a02b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74:491\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2015.10.043.","journal-title":"J Am Acad Dermatol"},{"key":"3124_CR16","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1111\/all.15439","volume":"77","author":"LS Spekhorst","year":"2022","unstructured":"Spekhorst LS, Bakker D, Drylewiczet J, et al. Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis. Allergy. 2022;77:3398\u2013407. https:\/\/doi.org\/10.1111\/all.15439.","journal-title":"Allergy"},{"key":"3124_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","volume":"156","author":"M Worm","year":"2020","unstructured":"Worm M, Simpson EL, Tha\u00e7i D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:131\u201343. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3617.","journal-title":"JAMA Dermatol"},{"key":"3124_CR18","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/bjd.21628","volume":"187","author":"F Jendoubi","year":"2022","unstructured":"Jendoubi F, Shourik J, Seneschal J, et al. Longer dupilumab dosing intervals in adult patients with atopic dermatitis: experience from a French multicentre retrospective cohort study. Br J Dermatol. 2022;187:602\u20133. https:\/\/doi.org\/10.1111\/bjd.21628.","journal-title":"Br J Dermatol"},{"key":"3124_CR19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/bjd\/ljad159","volume":"189","author":"LS Spekhorst","year":"2023","unstructured":"Spekhorst LS, Boesjes CM, Loman L, et al. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry. Br J Dermatol. 2023;189:327\u201335. https:\/\/doi.org\/10.1093\/bjd\/ljad159.","journal-title":"Br J Dermatol"},{"key":"3124_CR20","doi-asserted-by":"publisher","first-page":"2235041","DOI":"10.1080\/09546634.2023.2235041","volume":"34","author":"A Chiricozzi","year":"2023","unstructured":"Chiricozzi A, Dal Bello G, Gori N, et al. Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study. J Dermatolog Treat. 2023;34:2235041. https:\/\/doi.org\/10.1080\/09546634.2023.2235041.","journal-title":"J Dermatolog Treat"},{"key":"3124_CR21","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.jid.2023.03.1659","volume":"143","author":"C Dekkers","year":"2023","unstructured":"Dekkers C, van der Wal MM, El Amrani M, et al. Biological tipping point in patients with atopic dermatitis treated with different dosing intervals of dupilumab. J Invest Dermatol. 2023;143:1822-5.e3. https:\/\/doi.org\/10.1016\/j.jid.2023.03.1659.","journal-title":"J Invest Dermatol"},{"key":"3124_CR22","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1111\/jdv.19391","volume":"37","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Silverberg JI, Tha\u00e7i D, et al. Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: results from a phase\u00a02b, randomized, controlled trial. J Eur Acad Dermatol Venereol. 2023;37:2558\u201368. https:\/\/doi.org\/10.1111\/jdv.19391.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03124-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03124-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03124-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T07:07:26Z","timestamp":1742713646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03124-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3124"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03124-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sonja St\u00e4nder is an investigator for Celldex, Galderma, GSK, Incyte, Kiniksa Pharmaceuticals, and Trevi Therapeutics; a consultancy\/advisory board member for AbbVie, Almirall, Beiersdorf, Clexio Biosciences, Eli Lilly, Galderma, Incyte, Integrity CE, Kiniksa Pharmaceuticals, KliRNA Biotech, Pfizer, Professor Paul Gerson Unna Academy, Sanofi, Touch IME, Vifor Pharma, and WebMD; and a speaker for AbbVie, BMS, Eli Lilly, FOMF, Galderma, LEO Pharma, L'Or\u00e9al, MEDahead, moroscience, Novartis, Pfizer, Professor Paul Gerson Unna Academy, Sanofi, UCB, and Vifor Pharma. Gil Yosipovitch is an advisory board member for AbbVie, Almirall, Amgen, Arcutis, Celldex, Eli Lilly, Escient Health, Galderma, GSK, Kamari, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals Inc., Sanofi, and Vifor Pharma; received grants\/research funding from AbbVie, Celldex, Galderma, Eli Lilly, Escient, LEO Pharma, Novartis, Pfizer, and Sanofi-Regeneron Pharmaceuticals Inc.; and is an investigator for Sanofi-Regeneron Pharmaceuticals Inc. Eric L. Simpson has received personal fees from AbbVie, Amgen, Arcutis Biotherapeutics, Areteia Therapeutics, BMS, CorEvitas, Corvus, Dermira, Eli Lilly, Evelo Biosciences, FIDE, Forte Biosciences, Galderma, Gilead, GlaxoSmithKline, Impetus Healthcare, Incyte, Innovaderm Research, Janssen, Johnson & Johnson, Kyowa Kirin Pharmaceutical Development, LEO Pharma, Merck, Numab Therapeutics, Pfizer, Physicians World, PRImE, Recludix Pharma, Regeneron Pharmaceuticals Inc., Roivant Sciences, Sanofi\/Genzyme, Sitryx Therapeutics, Trevi Therapeutics, and Valeant; and reports grants (or serves as Principal investigator) for AbbVie, Acrotech, Amgen, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Castle Biosciences, CorEvitas, Dermavant, Dermira, Incyte, Lilly, Kymab, Kyowa Kirin, LEO Pharma, National Jewish Health, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, Target, and VeriSkin. Brian S. Kim is co-founder of Alys Pharmaceuticals; has served as a consultant for 23andMe, ABRAX Japan, AbbVie, Amgen, Attovia Therapeutics, Cara Therapeutics, Clexio Biosciences, Eli Lilly and Company, Escient Pharmaceuticals, Evommune, Galderma, LEO Pharma, Micreos, Novartis, Pfizer, Recens Medical, Regeneron, Sanofi, Septerna, Teva, Trevi Therapeutics, Triveni Bio, WebMD; has stock in ABRAX Japan, Alys Pharmaceuticals, Attovia Therapeutics, Locus Biosciences, Recens Medical, and Triveni Bio; holds a patent for the use of JAK1 inhibitors for chronic pruritus. Kenji Kabashima has received honoraria for lectures from Eli Lilly, Japan Tobacco, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, and Procter & Gamble; and research grants from Kyoto Hakko Kirin, Mitsubishi Tanabe Pharma, and Ono Pharmaceutical. Diamant Tha\u00e7i is an advisor, speaker, or consultant for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Galderma, Janssen, Kyowa Kirin, LEO Pharma, Lilly, L'Or\u00e9al, New Bridge, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi\/Genzyme, Target RWE, UCB, and Vichy. Martin Metz has received honoraria as a speaker and\/or advisor for AbbVie, ALK-Abello, Almirall, Amgen, argenx, AstraZeneca, Bayer, Beiersdorf, Celldex, Celltrion, Escient Pharmaceuticals, Galderma, GSK, Incyte, Jasper, Novartis, Pfizer, Pharvaris, Regeneron Pharmaceuticals Inc., Sanofi, Teva, Third Harmonic Bio, and Vifor Pharma. Zhen Chen and Sandra Hagen are employees and shareholders of Regeneron Pharmaceuticals Inc. Mike Bastian is an employee and may hold stock and\/or stock options in Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guideline, and applicable regulatory requirements. An independent data and safety monitoring committee conducted blinded monitoring of patient safety data. The local institutional review board or ethics committee at each study center oversaw trial conduct and documentation. Signed written informed consent was obtained from all patients participating in both trials.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}